Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049988 | 0.83 | HRH3 (0.50) | HRH3ALDH1A1MAPTCNR2PYCR1 | |
| SCHEMBL3400632 | 0.83 | HRH3 (0.50) | HRH3ALDH1A1MAPTCNR2PYCR1 | |
| SCHEMBL14373882 | 0.83 | PYCR1 (0.53) | ALDH1A1MEN1KMT2AMAPTCNR2 | |
| SCHEMBL20287494 | 0.82 | HRH3 (0.72) | HRH3MAPTPYCR1NPSR1CYP2C19 | |
| Hydrochloric Acid SCHEMBL5025947 | 0.81 | PYCR1 (0.52) | ALDH1A1MAPTPOLBCNR2PYCR1 | |
| SCHEMBL6261922 | 0.80 | HRH3 (0.47) | HRH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6268546 | 0.79 | ALDH1A1 (0.49) | HRH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL28783183 | 0.78 | MAPT (0.69) | HRH3ALDH1A1MAPTMCHR1 | |
| SCHEMBL995037 | 0.77 | TAAR1 (0.43) | HRH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6268253 | 0.77 | PYCR1 (0.53) | HRH3ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217989-A1 | MACROCYCLIC BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-08-03 | — | — | US | disclosed |
| US-20160280650-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-29 | — | — | US | disclosed |
| US-9365529-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVLOPMENT (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2968314-A2 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | Galderma Research & Development (FR) | 2016-01-20 | — | — | EP | disclosed |
| US-20150158834-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-06-11 | — | — | US | disclosed |
| US-8980897-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-17 | — | — | US | disclosed |
| EP-2801568-A1 | Benzene-sulphonamide compounds, method for synthesising and use in medicine and in cosmetics | Galderma Research & Development (FR) | 2014-11-12 | — | — | EP | disclosed |
| WO-2014140861-A2 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275108-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-09-18 | — | — | US | disclosed |
| EP-2448920-B1 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine | GALDERMA RES & DEV (FR) | 2014-08-13 | — | — | EP | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6172057-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0973512-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998037877-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280650-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, NISCH | HRH3 1598/4885ALDH1A1 318/4885MEN1 2111/4885 |
| US-20140275108-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | NOTUM, CBS, TST | HRH3 1325/4885ALDH1A1 274/4885MEN1 3601/4885 |
| US-20150158834-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, NISCH | HRH3 1598/4885ALDH1A1 318/4885MEN1 2111/4885 |
| US-20170217989-A1 | MACROCYCLIC BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | ZC3HAV1, HAVCR2, HCCS | HRH3 4523/4885ALDH1A1 530/4885MEN1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.